Caxton Associates (UK)’s Atrium Therapeutics RNA Stock Holding History

Caxton Associates (UK)’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$595K	Hold	44,230	–	–	0.01%	504
2026 Q1	$591K	Buy	+44,230	New	+$621K	0.01%	472

Other funds holding RNA

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Caxton Associates (UK)'s RNA Position: Q2 2026 in Review

Caxton Associates (UK) held its Atrium Therapeutics (RNA) position steady in Q2 2026 at 44,230 shares worth $595K. The position accounts for 0.01% of the portfolio, ranked #504.

Caxton Associates (UK) first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. 155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

Caxton Associates (UK) held 44,230 shares of Atrium Therapeutics worth $595K as of Q2 2026.
Caxton Associates (UK) left its Atrium Therapeutics share count unchanged in Q2 2026.
Atrium Therapeutics made up 0.01% of Caxton Associates (UK)'s portfolio in Q2 2026, its #504 holding.
Caxton Associates (UK) first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.